


## eTheRNA, VUB expand collaboration to engineer next-generation mRNA therapeutics

23 June 2021 | News

TetraMix, a new generation of the TriMix adjuvant technology, intends to boost dendritic cell activation



eTheRNA immunotherapies, a clinical-stage company developing mRNA-based immunotherapies for the treatment of cancer and infectious diseases, has announced the expansion of its strategic collaboration with Vrije Universiteit Brussel (VUB) with the signing of an exclusive license for TetraMix, a new generation of the TriMix adjuvant technology.

Clinical and preclinical data have demonstrated clinical safety of TriMix, together with its ability to amplify immune responses in multiple disease indications. This new license stems from the collaboration between the VUB and eTheRNA focussed on directed activation of dendritic cells and leverages research performed at the Laboratory for Molecular and Cellular Therapy (LMCT) of the VUB. In the presence of specific antigens, dendritic cells behave as immune response modulators, directing the immune system to attack target cells through the activation of directed CD4+ T-helper and CD8+ cytotoxic T-cell responses.

"We have already demonstrated that TriMix has a benign safety profile and promotes high mRNA expression levels," comments Steven Powell, CEO, eTheRNA. "TetraMix will now be integrated into our programmes to engineering new generation mRNA immunotherapies offering even greater efficacy and immunogenicity."

"VUB has been an internationally recognised centre of excellence for RNA research for the last decade with numerous breakthroughs originating from LMCT," comments Professor Dr Karine Breckpot, Director, LMCT. "TriMix's robustness and versatility as an immune stimulatory platform have been proven in several clinical indications and we are delighted to now introducing TetraMix. We are confident that TetraMix's new way of immune activation will certainly set a precedent for future immunotherapies."